Shield Arming Itself With Axis For Cardio Diagnostics Market Campaign
This article was originally published in The Gray Sheet
Executive Summary
Shield Diagnostics Group PLC's proposed merger with Olso, Norway-based Axis Biochemicals ASA, is an attempt to combine the companies' cardiovascular disease diagnostics technology to be supplied to hospital labs with clinical chemistry or immunoassay analyzers, the firms said Jan. 18.
You may also be interested in...
Global Diagnostics In Brief
Computer-aided detection: Siemens Medical's Mammomat Novation digital mammography system will integrate iCAD's Second Look Digital software as part of a three-year, worldwide licensing and distribution agreement. In a July 8 release, iCAD notes that U.S. product release is slated for 2005, following FDA approval of Mammomat, already cleared internationally. Last month, iCAD announced integration of its film-based analysis tool, Second Look 500M, with Confirma's MRI CAD to aid breast cancer detection....CADstream: Kirkland, Wash.-based Confirma launches CADstream 3.1 next-gen breast MRI analysis device July 8, following 510(k) clearance the previous day. The system includes SureLoc technology, allowing "automatic CAD-analysis and reporting of lesion location and calculations at the point of procedure," Confirma states. Other features include enhanced remote viewing and automatic reading capability within a 2-D region of interest. On July 1, GE Healthcare said it would distribute CADstream software to its global MRI customers...
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.